Fermatron Plus synovial fluid prosthesis solution 1.5%, No. 1

Fermatron Plus synovial fluid prosthesis solution 1.5%, No. 1; To relieve pain and stiffness in the knee, hip, ankle and shoulder joints of patients suffering from mild to moderate osteoarthritis resulting from degenerative and traumatic changes in the synovial joint.

Fermatron Plus injections should only be performed by a healthcare professional trained in the appropriate technique. For patients with mild or moderate knee osteoarthritis, it is recommended to inject 2.0 ml of the drug into the synovial cavity of the knee joint once a week for 1-3 weeks.

The healthcare professional should clarify the dosing regimen for injections into the synovial space of the hip, ankle and shoulder joints. It is recommended that injections be performed in the hip, ankle and shoulder joints under ultrasound or fluoroscopic guidance. Before the introduction of the drug, the injection site must be treated with an antiseptic and allowed to dry. If there is an articular effusion, it must be removed before the administration of Fermatron Plus. The contents of the syringe are sterile. The introduction should be made using a sterile needle of the appropriate gauge (it is recommended to use a needle from 18 to 21 G). The syringe is equipped with a Luer Lok Щ (6%) connector for a secure connection of the needle to the syringe. The syringe and needle should be discarded after a single use.

Sodium hyaluronate, mg / ml - 14.0 - 16.0

Sodium chloride, mg / ml - 8.5 - 9.5

Phosphates, mg / ml - 0.15-0.25

Do not administer Fermatron Plus if there is inflammation or signs of skin diseases at the injection site. Do not use in patients with known hypersensitivity to sodium hyaluronate.

Sodium hyaluronate is a long chain polysaccharide. It consists of repeating disaccharide units of D-glucuronic acid and N-acetyl-O-glucosamine and is a natural component of the human body. Fermatron Plus has a pH similar to that of synovial fluid.

Adverse Reactions

With intra-articular administration, temporary passing pain and swelling are possible. In rare cases, an inflammatory reaction, septic arthritis or arthralgia may occur, which may or may not be associated with Fermatron Plus.

Interaction

The compatibility of the simultaneous intra-articular administration of the drug Fermatron Plus with other substances has not been tested. Therefore, mixing or simultaneous administration of other intra-articular drugs is not recommended.